News

Arrowhead said it is on track to earn the $100 million DM1 milestone soon and pocket the remaining $200 million by the end of the year. If Sarepta fails to make either payment, Arrowhead would ...
Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease treatment that is currently being considered for approval by Chinese ...